Találati lista | Tudóstér

001-es BibID:	BIBFORM118904
035-os BibID:	(cikkazonosító)530
Első szerző:	Nagy Nikolett (belgyógyász)
Cím:	Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus / Nagy Nikolett, Bói Bernadett, Papp Gábor, Fiák Edit, Gáspár-Kiss Eszter, Perge Bianka, Farmasi Nikolett, Tarr Tünde
Dátum:	2024
ISSN:	2227-9059
Megjegyzések:	In systemic lupus erythematosus (SLE), cardiovascular complications are among the leading causes of death. Cardiovascular risk in SLE is even higher in the presence of antiphospholipid antibodies or secondary antiphospholipid syndrome (APS). The aim of this retrospective, single-center study was to investigate the occurrence of antiphospholipid antibodies and non-thrombotic cardiac manifestations in 369 SLE patients. We also assessed the clinical and laboratory characteristics of the patients to reveal the risk factors for cardiac manifestations. Patients were divided into two groups based on the presence of antiphospholipid antibodies (APA); 258 (69.9%) patients were APA positive, and 111 (30.1%) patients were APA negative. Mitral and tricuspid insufficiency, aortic stenosis and pulmonary arterial hypertension were more common in APA-positive patients. Anticardiolipin IgG showed the strongest correlation with any non-thrombotic cardiac manifestations. Based on our results, the adjusted global antiphospholipid syndrome score (aGAPSS) above 8.5 is predictive of valvulopathies and ischemic heart disease, while aGAPSS above 9.5 is predictive of cardiomyopathies. The presence of antiphospholipid antibodies may affect the development of cardiac manifestations in SLE. Periodic cardiological and echocardiographic screening of patients without cardiac complaints, as well as regular monitoring of antiphospholipid antibodies, have great importance during the treatment of SLE patients.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk systemic lupus erythematosus antiphospholipid antibodies non-thrombotic cardiac manifestations aGAPSS
Megjelenés:	Biomedicines. - 12 : 3 (2024), p. 1-15. -
További szerzők:	Bói Bernadett Papp Gábor (1984-) (belgyógyász) Fiák Edit Gáspár-Kiss Eszter (1997-) (rezidens) Perge Bianka Farmasi Nikolett (1989-) (orvos) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus)
Pályázati támogatás:	OTKA-124177 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM110898
035-os BibID:	(cikkazonosító)1218 (WoS)000977128900001 (Scopus)85153720382
Első szerző:	Nagy Nikolett (belgyógyász)
Cím:	Changes in Clinical Manifestations and Course of Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome over Three Decades / Nagy Nikolett, Papp Gábor, Gáspár-Kiss Eszter, Diószegi Ágnes, Tarr Tünde
Dátum:	2023
ISSN:	2227-9059
Megjegyzések:	Systemic lupus erythematosus (SLE) is often associated with antiphospholipid syndrome (APS), which potentially results in a more severe disease course and reduced life expectancy. Since the therapeutic guidelines have been refined in the last 15 years, we assumed that the diseases course has become more favorable. In order to shed light on these achievements, we compared the data of SLE patients diagnosed before and since 2004. In our retrospective study, we assessed a wide spectrum of clinical and laboratory data of 554 SLE patients who received regular follow-up care and therapy at our autoimmune center. Among these patients, 247 had antiphospholipid antibodies (APAs) without clinical signs of APS, and 113 had definitive APS. In the APS group, among patients diagnosed since 2004, deep vein thrombosis (p = 0.049) and lupus anticoagulant positivity (p = 0.045) were more frequent, while acute myocardial infarction was less frequent (p = 0.021) compared with patients diagnosed before 2004. Among the APA positive patients without definitive APS, anti-cardiolipin antibody positivity (p = 0.024) and development of chronic renal failure (p = 0.005) decreased in patients diagnosed since 2004. Our study demonstrates that the disease course has changed in recent years; however, in the presence of APS, we have to expect repeated thrombotic events despite adequate anticoagulant therapy.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk systemic lupus erythematosus antiphospholipid syndrome disease course therapy
Megjelenés:	Biomedicines. - 11 : 4 (2023), p. 1-10. -
További szerzők:	Papp Gábor (1984-) (belgyógyász) Gáspár-Kiss Eszter (1997-) (rezidens) Diószegi Ágnes (1987-) (belgyógyász) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus)
Pályázati támogatás:	K 124177 NKFIH
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: